ReviewCancers2021

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.

Xabier Mielgo-Rubio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.